Milvexian FXIa Inhibition for Stroke Prevention With Lower Bleeding Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic treatments for ischemic stroke and transient ischemic attack (TIA) are limited by high residual risk of recurrent events and increased bleeding risk, despite standard antiplatelet therapies and dual antiplatelet therapy (DAPT).
Innovation Solution
A treatment regimen combining an oral formulation of milvexian, a potent and selective FXIa inhibitor, with standard of care antiplatelet therapy (DAPT) to inhibit activated factor XI (FXIa) and platelet activation, reducing thrombin generation while preserving hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antiplatelet therapy or dual antiplatelet therapy (DAPT) is used to prevent ischemic stroke, then the risk of recurrent stroke is reduced, but the bleeding risk increases
Solution Approach 1:
The patent applies parameter changes by switching from antiplatelet therapy to anticoagulant therapy with apixaban, which has a different mechanism of action (direct factor Xa inhibition). This pharmacological parameter change allows for effective stroke prevention while potentially modifying the bleeding profile compared to traditional antiplatelet agents
Solution Approach 2:
The patent introduces an intermediary substance (apixaban) that mediates between the need for stroke prevention and the concern for bleeding risk. By using a direct factor Xa inhibitor as an intermediary mechanism, the therapy targets the coagulation cascade specifically to prevent thrombus formation without the same bleeding risks associated with antiplatelet therapy
2Reliability
If more intensive antiplatelet therapy is used to further reduce stroke risk, then the protective effect against ischemic events increases, but the bleeding complications increase
Solution Approach 1:
The patent employs a short-acting reversible anticoagulant (apixaban) that can be administered in a time-limited manner (3-6 months) to provide intensive protection when most needed, then discontinued or de-escalated. This allows for intensive therapy during the high-risk period without committing to long-term intensive anticoagulation that would increase cumulative bleeding risk
Solution Approach 2:
The patent implements periodic action by limiting the duration of intensive anticoagulant therapy to a specific time window (3-6 months) following the index stroke. This periodic intensive therapy provides maximum protection during the period of highest recurrence risk while avoiding unnecessary long-term exposure that would increase bleeding complications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen effectively reduces the risk of recurrent ischemic stroke by approximately 30-40% without significantly increasing bleeding risk, providing a favorable balance between ischemic and bleeding outcomes compared to antiplatelet therapy alone.
Implementation Method 1
milvexian, a potent and selective FXIa inhibitor
Implementation Method 2
preserving hemostasis
Data Source
AI summary
A Factor XIa inhibitor having therapeutic properties useful in methods for treating or preventing ischemic stroke.